Bremelanotide Acetate (PT-141 Acetate), a synthetic peptide analogue of α-MSH, is an agonist at melanocortin receptors including the MC3R and MC4R for the treatment of sexual dysfunction.. In Vivo: Bremelanotide Acetate (50-200 μg/kg; s.c.; once) significantly increases proceptive solicitations in females primed with Estradiol benzoate+Progesterone or Estradiol benzoate alone in bilevel chambers.
Bremelanotide is a novel drug candidate for the treatment of male and female sexual dysfunction. Bremelanotide has shown promise in effectively treating erectile dysfunction (ED) without the cardiovascular effects found in ED drugs currently available. Bremelanotide works through a mechanism of action involving the central nervous system rather than directly on the vascular system. As a result, it may offer significant safety and efficacy benefits over currently available products.
Bremelanotide Acetate works by activating melanocortin receptors in the central nervous system, primarily the melanocortin 4 receptor (MC4R). The melanocortin system is known to play a critical role in a variety of physiological processes, including energy homeostasis, inflammation, and sexual function.
The most common adverse reactions reported include nausea, flushing, injection site reactions, and headache.
Bremelanotide Acetate (50-200 μg/kg; s.c.; once) significantly increases proceptive solicitations in females primed with Estradiol benzoate+Progesterone or Estradiol benzoate alone in bilevel chambers[2].
| Animal Model: | Ovariectomized Long–Evans rats[2] |
| Dosage: | 50, 100, 200 μg/kg |
| Administration: | s.c.; once |
| Result: | Significantly increased proceptive solicitations in females primed with Estradiol benzoate+Progesterone or Estradiol benzoate alone in bilevel chambers. |
